Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B12 in kidney transplant recipients

Kidney International

Volumn 67, Issue 5, 2005, Pages 1980-1985

  Winkelmayer, Wolfgang C ^b   Huber, Andrea ^b   Wagner, Oswald F ^b   Hörl, Walter H ^b   Sunder Plassmann, Gere ^b   Födinger, Manuela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Folate; Genetic polymorphism; Homocysteine; Kidney transplants; MTHFR; Mutation; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGED; ARTICLE; BODY MASS; FEMALE; FOLIC ACID BLOOD LEVEL; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MTHFR 1298A C GENE; MTHFR 1793A A GENE; MTHFR 1793G A GENE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT;

EID: 17744375990     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00298.x     Document Type: Article

References (30)

1. HANKEY GJ, EIKELBOOM JW: Homocysteine and vascular disease. Lancet 354:407-43, 1999
2. THE HOMOCYSTEINE STUDIES COLLABORATION. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288:2015-2022, 2002
3. BOSTOM AG, CULLETON BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10:891-900, 1999
4. FÖDINGER M, HÖRL WH, SUNDER-PLASSMANN G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 13:20-33. 2000
5. WINKELMAYER WC, EBERLE C, FÖDINGER M, Sunder-Plassmann G: Effects of the glutamate carboxypeptidase II (GCP2 1561 C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney Int 63:2280-2285, 2003
6. FÖDINGER M, DIERKES J, SKOUPY S, et al: Effect of glutamate carboxypeptidase II and reduced folate carrier polymorphisms on folate and total homocysteine concentrations in dialysis patients. J Am Soc Nephrol 14:1314-1319, 2003
7. 12 concentrations in renal transplant patients. Atherosclerosis 174:43-48, 2004
8. 12 cellular availability in end-stage renal disease patients. Kidney Int 64:1095-1100, 2003
9. 12, folate, and total homocysteine levels in kidney transplant patients. Kidney Int 65:1877-1881, 2004
10. RADY PL, SZUCS S, GRADY J, et al: Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 107:162-168, 2002
11. WINKELMAYER WC, SUNDER-PLASSMANN G, HUBER A, FÖDINGER M: Patterns of co-occurrence of three single nucleotide polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene in kidney transplant recipients. Eur J Clin Invest 34:613-618, 2004
12. 12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 11:1918-1925, 2000
13. AMERICAN SOCIETY OF HUMAN GENETICS/AMERICAN COLLEGE OF MEDICAL GENETICS TEST AND TECHNOLOGY TRANSFER COMMITTEE WORKING GROUP: ASHG/ACMG statement. Measurement and use of total plasma homocysteine. Am J Hum Genet 63:1541-1543, 1998
14. COCKCROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
15. FROSST P, BLOM HJ, MILOS R, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase [letter]. Nat Genet 10:111-113, 1995
16. WEISBERG I, TRAN P, CHRISTENSEN B. et al: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172, 1998
17. THOMPSON SG, BARBER JA: How should cost data in pragmatic randomised trials be analysed? Br Med J 320:1197-1200, 2000
18. DIEHR P, YANEZ D, ASH A, et al: Methods for analyzing health care utilization and costs. Annu Rev Public Health 20:125-144, 1999
19. GOODMAN SN, BERLIN JA: The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 121:200-206, 1994
20. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification: Part 4. Definition and classification of stages of chronic kidney disease Am J Kidney Dis 37 (Suppl 1):S46-S75, 2002
21. KOCSIS I, GYÖRFFY B, NÉMETH E, VÁSÁRHELYI B: Examination of Hardy-Weinberg equilibrium in papers of Kidney International: An underused tool. Kidney Int 65:1956-1958, 2004
22. WINKELMAYER WC, KRAMAR R, CURHAN GC, et al: Fasting plasma total-homocysteine levels and mortality and allograft loss in kidney transplant recipients - A prospective study. J Am Soc Nephrol 16:255-260, 2005
23. Burtis CA, Ashwood ER, eds: Tietz Textbook of Clinical Chemistry, 2nd ed., Philadelphia, WB Saunders Company, 1994, pp 2049-2053
24. 12. Proc Nutr Soc 58:441-448, 1999
25. FOWLER B: The folate cycle and disease in humans. Kidney Int 59 (Suppl 78):S221-S229, 2001
26. SAVAGE DG, LINDENBAUM J, STABLER SP, ALLEN RH: Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-249, 1994
27. DUCLOUX D, MOTTE G, CHALLIER B, et al: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11:134-137, 2000
28. CHEN Z, CRIPPEN K, GULATI S, BANERJEE R: Purification and kinetic mechanism of a mammalian methionine synthase from pig liver. J Biol Chem 269:27193-27197, 1994
29. LINDENBAUM J, ALLEN RH: Clinical spectrum and diagnosis of folate deficiency, in Folate in Health and Disease, edited by Bailey LB, New York, NY, Marcel Dekker Inc., 1995, pp 43-73
30. 12 and folate deficiency: A guide for the primary care physician. Arch Int Med 159:1289-1298, 1999